ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

SaveRxCanada.to Offers Access to Affordable Tagrisso (Osimertinib) from India





Save Over $5,000 Monthly with a trusted international online pharmacy for over 20 years

VANCOUVER, BC, April 11, 2025 /24-7PressRelease/ -- SaveRxCanada.to, a trusted international online pharmacy, is now helping U.S. patients access the life-extending lung cancer drug Tagrisso (also known by its generic name Osimertinib) at significantly reduced prices through licensed suppliers in India. With monthly savings of up to $5,500 USD, patients can potentially save more than $66,000 USD annually.

Developed by AstraZeneca, Tagrisso is a targeted therapy used to treat non-small cell lung cancer (NSCLC) with EGFR mutations. It has become the standard of care for patients with both common EGFR mutations and the resistant T790M mutation, offering improved survival outcomes and quality of life.

Breakthrough Lung Cancer Therapy at a Fraction of the U.S. Price

In the United States, a 30-tablet supply of Tagrisso can cost between $15,000 to $18,000 USD per month. Through SaveRxCanada.to's partnered suppliers in India, the same branded 80 mg tablets from AstraZeneca are available for $416.67 USD per tablet—bringing the monthly cost to approximately $12,500 USD. This means U.S. patients could save up to $5,500 USD every month without compromising on drug quality or efficacy.

"We're proud to make life-saving treatments more affordable," says SaveRxCanada.to. "Our service provides access to genuine medication from licensed international suppliers, ensuring safety, authenticity, and substantial cost savings."

What is Tagrisso?

Tagrisso is an EGFR tyrosine kinase inhibitor (TKI) designed for:

• First-line treatment of EGFR-mutant NSCLC
• Patients whose cancer has progressed after earlier EGFR-targeted therapy
• Targeting both common EGFR mutations and the T790M resistance mutation

Common Side Effects

While generally well-tolerated, some common side effects of Osimertinib include:

• Diarrhea
• Rash
• Dry skin and nail inflammation
• Fatigue
• Decreased appetite

Rare but serious effects may include lung inflammation, heart rhythm problems (QT prolongation), and eye issues. Patients should always consult their oncologist before starting or switching treatment.

How to Order from SaveRxCanada.to

Patients need a valid prescription to order Tagrisso. SaveRxCanada.to partners with certified international suppliers who provide:

• Verification of product authenticity
• Prescription validation by a licensed pharmacist
• Secure shipping and cold-chain logistics, if needed

About SaveRxCanada.to

SaveRxCanada.to is an online pharmacy platform connecting North American consumers with safe and affordable medications from licensed international suppliers. The company is committed to helping patients manage high drug costs by offering genuine products at a fraction of U.S. retail prices.

For more information or to order Tagrisso, visit www.SaveRxCanada.to.



---
Press release service and press release distribution provided by https://www.24-7pressrelease.com
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.